Industry Developments

BMI View: Cipla's decision to cut the prices of three of its cancer drugs could significantly benefit patients in India and other developing countries, especially in Africa, who previously... 2012-05-08

BMI View: India's growing reputation as a pharmaceutical manufacturing hub is somewhat overhyped. The country exports medicines to developed states and emerging markets but these products... 2012-03-30

BMI View: India's issuance of a compulsory licence for a patented drug is highly significant for several key stakeholders. Patients will now have increased access to a medicine that... 2012-03-15

BMI View: India's pharmaceutical market is highly attractive to drugmakers but it also has several negative characteristics. Combined sales of over-the-counter (OTC) and prescription... 2012-03-05

BMI View: Singapore's latest budget is a positive development for patients and certain commercial enterprises as it shows the government is placing more emphasis on healthcare, especially... 2012-02-22

BMI View: Multinational pharmaceutical companies will benefit more from China's national and provincial drug reimbursement lists (DRLs) as opposed to its national and provincial essential... 2012-02-21

BMI View: China continues to be the key emerging market for most multinational pharmaceutical companies and we continue to expect increasing investment into the country. Despite a potential... 2012-02-16

BMI View: Despite increasing pharmaceutical exports, Malaysia is not expected to reverse its negative pharmaceutical trade balance, due to increasing domestic demands for sophisticated... 2012-02-15

BMI View: Australia's proposed changes to the Private Health Insurance (PHI) rebate scheme would mean the government will spend less on the provision of medical services. However, we... 2012-02-13

BMI View: Investor sentiment towards Takeda Pharmaceutical Company is improving. Japan's largest drugmaker is increasing its presence in emerging markets, rationalising global operations... 2012-02-09